These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17883284)

  • 1. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
    Andress D
    Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D; Bommer J; Coyne D
    Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
    Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
    Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.
    Panizo S; Barrio-Vázquez S; Naves-Díaz M; Carrillo-López N; Rodríguez I; Fernández-Vázquez A; Valdivielso JM; Thadhani R; Cannata-Andía JB
    Nephrol Dial Transplant; 2013 Nov; 28(11):2735-44. PubMed ID: 24013683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
    Dyer CA
    Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cai P; Tang X; Qin W; Ji L; Li Z
    Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J; Żebrowski P
    Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
    Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
    BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR; Melnick J
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
    Brancaccio D; Cozzolino M; Cannella G; Messa P; Bonomini M; Cancarini G; Caruso MR; Cascone C; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Blood Purif; 2011; 32(2):124-32. PubMed ID: 21625082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
    Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
    Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
    Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
    Cozzolino M; Brandenburg V
    Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
    Shinaberger CS; Kopple JD; Kovesdy CP; McAllister CJ; van Wyck D; Greenland S; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1769-76. PubMed ID: 18701614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
    Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
    J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
    Geng X; Shi E; Wang S; Song Y
    PLoS One; 2020; 15(5):e0233705. PubMed ID: 32470067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.